Abstract
Objective:
To critically review the potential effect of the public reporting of pharmaceutical company payments to healthcare professionals on the relationship between medicine and industry.
Method:
This review is based on an examination of the ‘Transparency Model’ put out recently for consultation by Medicines Australia.
Results:
Public reporting in itself will neither sharpen the boundaries between medicine and the pharmaceutical industry nor restore public confidence.
Conclusions:
Focusing on payments for clinical research and on the larger payments to healthcare professionals would lead to a better understanding of the interplay between science and marketing.
Get full access to this article
View all access options for this article.
